AVEO Pharmaceuticals (AVEO)

Add to Watchlists
Create an Alert
1.34 -0.05  -3.60% NASDAQ Apr 17, 8:00PM BATS Real time Currency in USD
View Full Chart
AVEO Price Chart
View All Events

AVEO Events

Date Type Description
Mar 13 Misc AVEO Pharmaceuticals Inc. Q4 2013 Earning Conference Call
Mar 13 Earnings AVEO Pharmaceuticals Inc. Q4 2013 Earning Result. Estimate: -0.40.
Nov 07 Earnings AVEO Reports Third Quarter 2013 Financial Results. Estimate: -0.41.
Aug 08 Earnings AVEO Reports Second Quarter 2013 Financial Results. Estimate: -0.59.
May 29 Misc AGM Event for AVEO Pharmaceuticals Inc
May 02 Misc AVEO Reports First Quarter 2013 Financial Results
Apr 29 Earnings AVEO Reports First Quarter 2013 Financial Results. Estimate: -0.67.
View All Performance Charts

AVEO Total Returns Comparison

This total returns chart shows the returns to an investor from both price appreciation and dividends (dividends are assumed to be reinvested). AVEO Pharmaceuticals is down 81.60% over the last year vs S&P 500 Total Return up 23.54%, Astellas Pharma down 1.15%, and Alexion Pharmaceuticals up 58.10%.

Get Quote for

Portfolio Strategies Featuring AVEO

Did AVEO Pharmaceuticals make it into our Portfolio Strategies?
Start your YCharts membership now to find out.

AVEO Profile

  • Sector: Healthcare
  • Industry: Biotechnology
  • Headquarters Country: United States
  • Headquarters State/Province: Massachusetts
  • Incorporation Country: United States
  • Incorporation State/Province: Delaware
  • Est. Current Fiscal Quarter End: June 30, 2014
  • Est. Current Fiscal Year End: December 31, 2014
  • Last Fiscal Quarter End: N/A
  • Last Fiscal Year End: N/A
  • NAICS: Pharmaceutical Preparation Manufacturing
  • NAICS Code: 325412
  • NAICS Industry: Pharmaceutical and Medicine Manufacturing
  • NAICS Industry Code: 3254
  • NAICS Sector: Manufacturing
  • NAICS Sector Code: 32

AVEO Pharmaceuticals is a cancer therapeutics company committed to discovering, developing and commercializing targeted therapies to impact patients’ lives. AVEO’s proprietary Human Response Platform™ provides the company unique insights into cancer biology and is being leveraged in the discovery and clinical development of its cancer therapeutics. AVEO Pharmaceuticals was formerly known as GenPath Pharmaceuticals, Inc. and changed its name to AVEO Pharmaceuticals, Inc. in March 2005. The company was founded by Ronald A. DePinho, Lynda Chin and Kenneth E. Weg on October 19, 2001 and is based in Cambridge, Massachusetts.

Recent Quotes

Symbol Price Chg Chg % Market Cap
AVEO 1.34 -0.05 -3.60% 69.40M
Create Watchlist from Quotes

Already registered? Click here to sign in.

Access watchlists and custom data alerts.
Start your free account.

Get Started Now

Upgrade to {{root.upsell.info.tier_name}}. Start Your YCharts Membership. Start your {{root.upsell.info.tier_name}} Membership


{{root.upsell.info.is_upgrade ? "Upgrade Now" : "Get Started Now"}}

Already a YCharts Member? Already a {{root.upsell.info.tier_name}} Member? Sign in here.